The lack of effects of PLC-β2 down-modulation on CD133 expression in CD133low cells confirms that the two sub-populations expressing different CD133 levels correspond to different stages of tumor differentiation, in which different signalling mechanisms take place. Here, PLCB2 is linked to neoplasm.